Effectiveness of regional chemotherapy with TNF-α/Melphalan in advanced soft tissue sarcoma of the extremities

International Journal of Hyperthermia

Volumn 24, Issue 3, 2008, Pages 193-203

  Taeger, G ^a   Grabellus, F ^a   Podleska, L E ^a   Muller S ^a   Ruchholtz, S ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Isolated limb perfusion; Limb salvage; Limb sarcoma; Radiotherapy; Soft tissue sarcoma; TNF

Indexed keywords

CISPLATIN; CYTOKINE; DACTINOMYCIN; DOXORUBICIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; IFOSFAMIDE; INTERFERON; MELPHALAN; OXYGEN; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TASONERMIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VITRONECTIN RECEPTOR;

ADJUVANT THERAPY; ADVANCED CANCER; BLISTER; CANCER CENTER; CANCER RADIOTHERAPY; CANCER REGRESSION; CELL INFILTRATION; CLINICAL TRIAL; COMPARTMENT SYNDROME; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG UPTAKE; EDEMA; ENDOPROSTHESIS; EPIDERMOLYSIS; EUROPE; EXTRACORPOREAL CIRCULATION; HEALTH CARE DELIVERY; HEALTH PROGRAM; HUMAN; HYPEREMIA; HYPERTHERMIC THERAPY; HYPOTENSION; INFLAMMATION; INHIBITION KINETICS; LIMB AMPUTATION; LIMB PERFUSION; MEDICAL DECISION MAKING; MULTIMODALITY CANCER THERAPY; NONHUMAN; OVERALL SURVIVAL; OXYGENATION; PATIENT MONITORING; PATIENT REFERRAL; PLASTIC SURGERY; POSTOPERATIVE PERIOD; PREOPERATIVE RADIOTHERAPY; PROTEIN EXPRESSION; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; TACHYCARDIA; TISSUE NECROSIS; TREATMENT OUTCOME; TUMOR CELL; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; UPREGULATION; VASCULAR SURGERY;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COMBINED MODALITY THERAPY; EXTREMITIES; HUMANS; HYPERTHERMIA, INDUCED; LIMB SALVAGE; MELPHALAN; SARCOMA; SOFT TISSUE NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 42049090876     PISSN: 02656736     EISSN: 14645157     Source Type: Journal    
DOI: 10.1080/02656730701868387     Document Type: Review

References (84)

1. Dickinson, IC, Whitwell, DJ, Battistuta, D., Thompson, B., Strobel, N., Duggal, A. and Steadman, P. (2006) Surgical margin and its influence on survival in soft tissue sarcoma. ANZ J Surg, 76, pp. 104-109.
2. McKee, MD, Liu, DF, Brooks, JJ, Gibbs, JF, Driscoll, DL and Kraybill, WG (2004) The prognostic significance of margin width for extremity and trunk sarcoma. J Surg Oncol, 85, pp. 68-76.
3. Stojadinovic, A., Leung, DH, Hoos, A., Jaques, DP, Lewis, JJ and Brennan, MF (2002) Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann Surg, 235, pp. 424-434.
4. Trovik, CS, Bauer, HC, Alvegard, TA, Anderson, H., Blomqvist, C., Berlin, O., Gustafson, P., Saeter, G. and Wallöe, A. (2000) Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 559 surgically-treated patients from the Scandinavian Sarcoma Group Register. Eur J Cancer, 36, pp. 710-716.
5. Rosenberg, SA, Tepper, J., Glatstein, E., Costa, J., Baker, A., Brennan, M., DeMoss, EV, Seipp, C., Sindelar, WF and Sugarbaker, P. (1982) The treatment of soft-tissue sarcomas of the extremities: Prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg, 196, pp. 305-315.
6. Stojadinovic, A., Jaques, DP, Leung, DH, Healey, JH and Brennan, MF (2001) Amputation for recurrent soft tissue sarcoma of the extremity: Indications and outcome. Ann Surg Oncol, 8, pp. 509-518.
7. Williard, WC, Hajdu, SI, Casper, ES and Brennan, MF (1992) Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg, 215, pp. 269-275.
8. Cormier, JN and Pollock, RE (2004) Soft tissue sarcomas. CA Cancer J Clin, 54, pp. 94-109.
9. Zagars, GK, Ballo, MT, Pisters, PW, Pollock, RE, Patel, SR and Benjamin, RS (2003) Surgical margins and reresection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapy. Cancer, 97, pp. 2544-2553.
10. Delaney, TF, Kepka, L., Goldberg, SI, Hornicek, FJ, Gebhardt, MC, Yoon, SS, Springfield, DS, Raskin, KA, Harmon, DC and Kirsch, DG (2007) Radiation therapy for control of soft-tissue sarcomas resected with positive margins. Int J Radiat Oncol Biol Phys, 67, pp. 1460-1469.
11. Kepka, L., Suit, HD, Goldberg, SI, Rosenberg, AE, Gebhardt, MC, Hornicek, FJ and Delaney, TF (2005) Results of radiation therapy performed after unplanned surgery (without re-excision) for soft tissue sarcomas. J Surg Oncol, 92, pp. 39-45.
12. Suit, HD, Mankin, HJ, Wood, WC and Proppe, KH (1985) Preoperative, intraoperative, and postoperative radiation in the treatment of primary soft tissue sarcoma. Cancer, 55, pp. 2659-2667.
13. Trovik, CS, Bauer, HC, Berlin, O., Tukiainen, E., Erlanson, M., Gustafson, P., Klepp, R., Saeter, G. and Wahlström, O. (2001) Local recurrence of deep-seated, high-grade, soft tissue sarcoma: 459 patients from the Scandinavian Sarcoma Group Register. Acta Orthop Scand, 72, pp. 160-166.
14. Pisters, PW, Harrison, LB, Woodruff, JM, Gaynor, JJ and Brennan, MF (1994) A prospective randomized trial of adjuvant brachytherapy in the management of low-grade soft tissue sarcomas of the extremity and superficial trunk. J Clin Oncol, 12, pp. 1150-1155.
15. Yang, JC, Chang, AE, Baker, AR, Sindelar, WF, Danforth, DN, Topalian, SL, DeLaney, T., Glatstein, E., Steinberg, SM and Merino, MJ (1998) Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol, 16, pp. 197-203.
16. Davis, AM, O'Sullivan, B., Turcotte, R., Bell, R., Catton, C., Chabot, P., Wunder, J., Hammond, A., Benk, V. and Kandel, R. (2005) Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol, 75, pp. 48-53.
17. O'Sullivan, B., Davis, AM, Turcotte, R., Bell, R., Catton, C., Chabot, P., Wunder, J., Kandel, R., Goddard, K. and Sadura, A. (2002) Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: A randomised trial. Lancet, 359, pp. 2235-2241.
18. Zagars, GK, Ballo, MT, Pisters, PW, Pollock, RE, Patel, SR and Benjamin, RS (2003) Preoperative versus postoperative radiation therapy for soft tissue sarcoma: A retrospective comparative evaluation of disease outcome. Int J Radiat Oncol Biol Phys, 56, pp. 482-488.
19. Cannon, CP, Ballo, MT, Zagars, GK, Mirza, AN, Lin, PP, Lewis, VO, Yasko, AW, Benjamin, RS and Pisters, PW (2006) Complications of combined modality treatment of primary lower extremity soft-tissue sarcomas. Cancer, 107, pp. 2455-2461.
20. Pisters, PW, O'Sullivan, B. and Maki, RG (2007) Evidence-based recommendations for local therapy for soft tissue sarcomas. J Clin Oncol, 25, pp. 1003-1008.
21. Tseng, JF, Ballo, MT, Langstein, HN, Wayne, JD, Cormier, JN, Hunt, KK, Feig, BW, Yasko, AW, Lewis, VO and Lin, PP (2006) The effect of preoperative radiotherapy and reconstructive surgery on wound complications after resection of extremity soft-tissue sarcomas. Ann Surg Oncol, 13, pp. 1209-1215.
22. Meric, F., Milas, M., Hunt, KK, Hess, KR, Pisters, PW, Hildebrandt, G., Patel, SR, Benjamin, RS, Plager, C. and Papadopolous, NE (2000) Impact of neoadjuvant chemotherapy on postoperative morbidity in soft tissue sarcomas. J Clin Oncol, 18, pp. 3378-3383.
23. Pisters, PW (2006) Preoperative chemotherapy and split-course radiation therapy for patients with localized soft tissue sarcomas: Home run, base hit, or strike out?. J Clin Oncol, 24, pp. 549-551.
24. Meric, F., Hess, KR, Varma, DG, Hunt, KK, Pisters, PW, Milas, KM, Patel, SR, Benjamin, RS, Plager, C. and Papadopoulos, NE (2002) Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas. Cancer, 95, pp. 1120-1126.
25. Pisters, PW, Patel, SR, Prieto, VG, Thall, PF, Lewis, VO, Feig, BW, Hunt, KK, Yasko, AW, Lin, PP and Jacobson, MG (2004) Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas. J Clin Oncol, 22, pp. 3375-3380.
26. DeLaney, TF, Spiro, IJ, Suit, HD, Gebhardt, MC, Hornicek, FJ, Mankin, HJ, Rosenberg, AL, Rosenthal, DI, Miryousefi, F. and Ancukiewicz, M. (2003) Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys, 56, pp. 1117-1127.
27. Kraybill, WG, Harris, J., Spiro, IJ, Ettinger, DS, DeLaney, TF, Blum, RH, Lucas, DR, Harmon, DC, Letson, GD and Eisenberg, B. (2006) Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. J Clin Oncol, 24, pp. 619-625.
28. Issels, RD (2006) High-risk soft tissue sarcoma: Clinical trial and hyperthermia combined chemotherapy. Int J Hyperthermia, 22, pp. 235-239.
29. Krementz, ET, Carter, RD, Sutherland, CM and Hutton, I. (1977) Chemotherapy of sarcomas of the limbs by regional perfusion. Ann Surg, 185, pp. 555-564.
30. van Ginkel, RJ, Schraffordt, KH, de Vries, EG, Molenaar, WM, Uges, DR and Hoekstra, HJ (1996) Hyperthermic isolated limb perfusion with cisplatin in four patients with sarcomas of soft tissue and bone. Eur J Surg Oncol, 22, pp. 528-531.
31. Fletcher, WS, Pommier, RF, Woltering, EA, Mueller, CR, Ash, KO and Small, KA (1994) Pharmacokinetics and results of dose escalation in cis-platin hyperthermic isolation limb perfusion. Ann Surg Oncol, 1, pp. 236-243.
32. Pommier, RF, Moseley, HS, Cohen, J., Huang, CS, Townsend, R. and Fletcher, WS (1988) Pharmacokinetics, toxicity, and short-term results of cisplatin hyperthermic isolated limb perfusion for soft-tissue sarcoma and melanoma of the extremities. Am J Surg, 155, pp. 667-671.
33. Rossi, CR, Vecchiato, A., Foletto, M., Nitti, D., Ninfo, V., Fornasiero, A., Sotti, G., Tregnaghi, A., Melanotte, P. and Lise, M. (1994) Phase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas. Cancer, 73, pp. 2140-2146.
34. Chapman, PB, Lester, TJ, Casper, ES, Gabrilove, JL, Wong, GY, Kempin, SJ, Gold, PJ, Welt, S., Warren, RS and Starnes, HF (1987) Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol, 5, pp. 1942-1951.
35. Eggimann, P., Chiolero, R., Chassot, PG, Lienard, D., Gerain, J. and Lejeune, F. (1995) Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs. Chest, 107, pp. 1074-1082.
36. Lienard, D., Ewalenko, P., Delmotte, JJ, Renard, N. and Lejeune, FJ (1992) High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol, 10, pp. 52-60.
37. Renard, N., Lienard, D., Lespagnard, L., Eggermont, A., Heimann, R. and Lejeune, F. (1994) Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha). Int J Cancer, 57, pp. 656-663.
38. Eggermont, AM, Schraffordt, KH, Klausner, JM, Kroon, BB, Schlag, PM, Liénard, D., van Geel, AN, Hoekstra, HJ, Meller, I. and Nieweg, OE (1996) Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg, 224, pp. 756-764.
39. Eggermont, AM, Schraffordt, KH, Liénard, D., Kroon, BB, van Geel, AN, Hoekstra, HJ and Lejeune, FJ (1996) Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: A multicenter trial. J Clin Oncol, 14, pp. 2653-2665.
40. Lejeune, F., Liénard, D., Eggermont, A., Schraffordt, KH, Rosenkaimer, F., Gérain, J., Klaase, J., Kroon, B., Vanderveken, J. and Schmitz, P. (1995) Administration of high-dose tumor necrosis factor alpha by isolation perfusion of the limbs. Rationale and results. J Infus Chemother, 5, pp. 73-81.
41. Lejeune, F., Liénard, D., Eggermont, A., Schraffordt, KH, Rosenkaimer, F., Gérain, J., Klaase, J., Kroon, B. and Schmitz, P. (1995) [Efficacy of the tumor necrosis factor-alpha (rTNF-alpha) associated with interferon-gamma and chemotherapy in extracorporeal circulation in the limb in inoperable malignant melanoma, soft tissue sarcoma and epidermoid carcinoma. A 4-year experience]. Bull Cancer, 82, pp. 561-567.
42. Posner, MC, Lienard, D., Lejeune, FJ, Rosenfelder, D. and Kirkwood, J. (1995) Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma. Cancer J Sci Am, 1, pp. 274-280.
43. Palladino Jr, MA, Shalaby, MR, Kramer, SM, Ferraiolo, BL, Baughman, RA, Deleo, AB, Crase, D., Marafino, B., Aggarwal, BB and Figari, IS (1987) Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: Induction of tumor-specific immunity. J Immunol, 138, pp. 4023-4032.
44. Hoving, S., Seynhaeve, AL, van Tiel, ST, de Wiel-Ambagtsheer, G aan, de Bruijn, EA, Eggermont, AM and Hagen, TL ten (2006) Early destruction of tumor vasculature in tumor necrosis factor-alpha-based isolated limb perfusion is responsible for tumor response. Anticancer Drugs, 17, pp. 949-959.
45. Eggermont, AM, de Wilt, JH and Hagen, TL ten (2003) Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol, 4, pp. 429-437.
46. Sijens, PE, Eggermont, AM, van Dijk, PV and Oudkerk, M. (1995) 31P-magnetic resonance spectroscopy as predictor of clinical response in human extremity sarcomas treated by single dose TNF-alpha + melphalan isolated limb perfusion. NMR Biomed, 8, pp. 215-224.
47. van Der, V., de Wilt, JH, Eggermont, AM, van Tiel, ST, Seynhaeve, AL and Hagen, TL ten (2000) TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br J Cancer, 82, pp. 973-980.
48. De Blaauw, I., Eggermont, AM, Deutz, NE, de Vries, M., Buurman, WA and Von Meyenfeldt, MF (1997) TNF-alpha has no direct in vivo metabolic effect on human muscle. Int J Cancer, 71, pp. 148-154.
49. Manusama, ER, Stavast, J., Durante, NM, Marquet, RL and Eggermont, AM (1996) Isolated limb perfusion with TNF alpha and melphalan in a rat osteosarcoma model: A new anti-tumour approach. Eur J Surg Oncol, 22, pp. 152-157.
50. de Wilt, JH, Hagen, TL ten, de Boeck, G., van Tiel, ST, de Bruijn, EA and Eggermont, AM (2000) Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer, 82, pp. 1000-1003.
51. van Etten, B., Vries, de MR, van Ijken, MG, Lans, TE, Guetens, G., Ambagtsheer, G., van Tiel, ST, de Boeck, G., de Bruijn, EA and Eggermont, AM (2003) Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusion. Br J Cancer, 88, pp. 314-319.
52. Ruegg, C., Yilmaz, A., Bieler, G., Bamat, J., Chaubert, P. and Lejeune, FJ (1998) Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med, 4, pp. 408-414.
53. Lejeune, FJ, Lienard, D., Matter, M. and Ruegg, C. (2006) Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun, 6, p. 6.
54. Filippo, F Di, Garinei, R., Anzá, M., Cavaliere, F., Botti, C., Perri, P. and Filippo, S Di (2003) Doxorubicin in isolation limb perfusion in the treatment of advanced limb soft tissue sarcoma. J Exp Clin Cancer Res, 22, pp. 81-817.
55. Thompson, JF and Gianoutsos, MP (1992) Isolated limb perfusion for melanoma: Effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg, 16, pp. 227-233.
56. Seynhaeve, AL, de Wilt, JH, van Tiel, ST, Eggermont, AM and Hagen, TL ten (2002) Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicity. Br J Cancer, 86, pp. 1174-1179.
57. Brunstein, F., Hoving, S., Seynhaeve, AL, van Tiel, ST, Guetens, G., de Bruijn, EA, Eggermont, AM and Hagen, TL ten (2004) Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies. J Natl Cancer Inst, 96, pp. 1603-1610.
58. Hoving, S., Brunstein, F., de Wiel-Ambagtsheer, G aan, van Tiel, ST, de Boeck, G., de Bruijn, EA, Eggermont, AM and Hagen, TL ten (2005) Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats. Cancer Res, 65, pp. 4300-4308.
59. Brunstein, F., Hoving, S., de Wiel-Ambagtsheer, G., de Bruijn, EA, Guetens, G., Eggermont, AM and Hagen, TL ten (2007) Decreased response rates by the combination of histamine and IL-2 in melphalan-based isolated limb perfusion. Cancer Immunol Immunother, 56, pp. 573-580.
60. Grunhagen, DJ, de Wilt, JH, Hagen, TL ten and Eggermont, AM (2006) Technology insight: Utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities. Nat Clin Pract Oncol, 3, pp. 94-103.
61. Manusama, ER, Nooijen, PT, Stavast, J., de Wilt, JH, Marquet, RL and Eggermont, AM (1998) Assessment of the role of neutrophils on the antitumor effect of TNF-alpha in an in vivo isolated limb perfusion model in sarcoma-bearing brown Norway rats. J Surg Res, 78, pp. 169-175.
62. de Wilt, JH, Manusama, ER, van Tiel, ST, van Ijken, MG, Hagen, TL ten and Eggermont, AM (1999) Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer, 80, pp. 161-166.
63. van Ginkel, RJ, Limburg, PC, Piers, DA, Koops, HS and Hoekstra, HJ (2002) Value of continuous leakage monitoring with radioactive iodine-131-labeled human serum albumin during hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Ann Surg Oncol, 9, pp. 355-363.
64. Thom, AK, Alexander, HR, Andrich, MP, Barker, WC, Rosenberg, SA and Fraker, DL (1995) Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan. J Clin Oncol, 13, pp. 264-273.
65. Hill, S., Fawcett, WJ, Sheldon, J., Soni, N., Williams, T. and Thomas, JM (1993) Low-dose tumour necrosis factor alpha and melphalan in hyperthermic isolated limb perfusion. Br J Surg, 80, pp. 995-997.
66. Rossi, CR, Foletto, M., Filippo, F Di, Vaglini, M., Anza, M., Azzarelli, A., Pilati, P., Mocellin, S. and Lise, M. (1999) Soft tissue limb sarcomas: Italian clinical trials with hyperthermic antiblastic perfusion. Cancer, 86, pp. 1742-1749.
67. Rossi, CR, Mocellin, S., Pilati, P., Foletto, M., Campana, L., Quintieri, L., De Salvo, GL and Lise, M. (2005) Hyperthermic isolated perfusion with low-dose tumor necrosis factor alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcomas. Ann Surg Oncol, 12, pp. 398-405.
68. Grunhagen, DJ, de Wilt, JH, van Geel, AN, Graveland, WJ, Verhoef, C. and Eggermont, AM (2005) TNF dose reduction in isolated limb perfusion. Eur J Surg Oncol, 31, pp. 1011-1019.
69. Sleijfer, S., van Ginkel, RJ, van der Mark, TW, Hoekstra, HJ, Zwaveling, JH, Schraffordt, KH and Mulder, NH (1997) Effects of hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan on pulmonary function assessments. J Immunother, 20, pp. 202-207.
70. Wieberdink, J., Benckhuysen, C., Braat, RP, van Slooten, EA and Olthuis, GA (1982) Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol, 18, pp. 905-910.
71. Noorda, EM, Vrouenraets, BC, Nieweg, OE, van, C Coeforden, van Slooten, GW and Kroon, BB (2003) Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities. Cancer, 98, pp. 1483-1490.
72. Hohenberger, P., Finke, LH and Schlag, PM (1996) Intracompartmental pressure during hyperthermic isolated limb perfusion for melanoma and sarcoma. Eur J Surg Oncol, 22, pp. 147-151.
73. Klicks, RJ, Vrouenraets, BC, Nieweg, OE and Kroon, BB (1998) Vascular complications of isolated limb perfusion. Eur J Surg Oncol, 24, pp. 288-291.
74. Eggermont, AM, Schraffordt, KH, Klausner, JM, Schlag, PM, Kroon, BB, Ben-Ari, G., van Geel, AN and Hagen, T ten (1999) Limb salvage by isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced extremity soft tissue sarcomas: Results of 270 perfusions in 246 patients. Proc Am Soc Clin Oncol USA, 11, p. 497.
75. Bonvalot, S., Laplanche, A., Lejeune, F., Stoeckle, E., Péchoux, C Le, Vanel, D., Terrier, P., Lumbroso, J., Ricard, M. and Antoni, G. (2005) Limb salvage with isolated perfusion for soft tissue sarcoma: Could less TNF-alpha be better?. Ann Oncol, 16, pp. 1061-1068.
76. Grunhagen, DJ, de Wilt, JH, Graveland, WJ, Verhoef, C., van Geel, AN and Eggermont, AM (2006) Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer, 106, pp. 1776-1784.
77. Gutman, M., Inbar, M., Lev-Shlush, D., Abu-Abid, S., Mozes, M., Chaitchik, S., Meller, I. and Klausner, JM (1997) High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer, 79, pp. 1129-1137.
78. Lans, TE, Grunhagen, DJ, de Wilt, JH, van Geel, AN and Eggermont, AM (2005) Isolated limb perfusions with tumor necrosis factor and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs. Ann Surg Oncol, 12, pp. 406-411.
79. Lejeune, FJ, Pujol, N., Liénard, D., Mosimann, F., Raffoul, W., Genton, A., Guillou, L., Landry, M., Chassot, PG and Chiolero, R. (2000) Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. Eur J Surg Oncol, 26, pp. 669-678.
80. Lev-Chelouche, D., Abu-Abeid, S., Kollander, Y., Meller, I., Isakov, J., Merimsky, O., Klausner, JM and Gutman, M. (1999) Multifocal soft tissue sarcoma: Limb salvage following hyperthermic isolated limb perfusion with high-dose tumor necrosis factor and melphalan. J Surg Oncol, 70, pp. 185-189.
81. Olieman, AF, Pras, E., van Ginkel, RJ, Molenaar, WM, Schraffordt, KH and Hoekstra, HJ (1998) Feasibility and efficacy of external beam radiotherapy after hyperthermic isolated limb perfusion with TNF-alpha and melphalan for limb-saving treatment in locally advanced extremity soft-tissue sarcoma. Int J Radiat Oncol Biol Phys, 40, pp. 807-814.
82. Grunhagen, DJ, de Wilt, JH, Graveland, WJ, van Geel, AN and Eggermont, AM (2006) The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma. Cancer, 106, pp. 156-162.
83. Hoven-Gondrie, ML, Thijssens, KM, Dungen, JJ Van den, Loonstra, J., van Ginkel, RJ and Hoekstra, HJ (2007) Long-term locoregional vascular morbidity after isolated limb perfusion and external-beam radiotherapy for soft tissue sarcoma of the extremity. Ann Surg Oncol, 14, pp. 2105-2112.
84. Thijssens, KM, van Ginkel, RJ, Pras, E., Suurmeijer, AJ and Hoekstra, HJ (2006) Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: The value of adjuvant radiotherapy. Ann Surg Oncol, 13, pp. 518-524.